Page last updated: 2024-11-06

andolast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

andolast: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65970
CHEMBL ID119549
SCHEMBL ID166170
MeSH IDM0409253

Synonyms (25)

Synonym
132640-22-3
andolast
4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]benzamide
CHEMBL119549
cr2039
andolast [inn]
benzamide, 4-(1h-tetrazol-5-yl)-n-(4-(1h-tetrazol-5-yl)phenyl)-
6513m33209 ,
4,4'-di-1h-tetrazol-5-ylbenzanilide
cr 2039
unii-6513m33209
cr-2039
4-(1h-tetrazol-5-yl)-n-(4-(1h-tetrazol-5-yl)phenyl)benzamide
SCHEMBL166170
DTXSID80157682
cr 2039; dizolast
SB18787
Q27263813
andolast (free base)
MS-25019
HY-106358
CS-0025647
andolast free base
benzamide, 4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]-
AKOS040747818

Research Excerpts

Overview

Andolast is a new airway specific anti-inflammatory agent.

ExcerptReferenceRelevance
"Andolast is a new airway specific anti-inflammatory agent. "( Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial).
Arshad, SH; D Amato, M; Giacovelli, G; Holgate, ST; Malerba, M; Radaeli, A; Rovati, L, 2015
)
2.24

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis was carried out using standard non-compartmental methods."( Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients.
Arshad, SH; D'Amato, M; Holgate, ST; Makovec, F; Persiani, S; Rovati, LC, 2001
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID182638Compound was evaluated for cytoprotective activity against sodium chloride-induced gastric lesions in male conscious rats1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID182634Compound was evaluated for cytoprotective activity against acetic acid-induced gastric lesions in male conscious rats1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID182637Compound was evaluated for cytoprotective activity against glucose-induced gastric lesions in male conscious rats1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID179611Antiallergic activity against rat passive cutaneous anaphylaxis (PCA) reaction induced by 25 mg/kg of ovalbumin given iv(bolus)1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID182635Cytoprotective activity against ethanol-induced gastric lesions in male conscious rats1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.70 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]